Vaxcyte Ownership
| PCVX Stock | USD 31.52 0.87 2.84% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 123.7 M | Current Value 122.8 M | Avarage Shares Outstanding 61.2 M | Quarterly Volatility 40.5 M |
Vaxcyte Stock Ownership Analysis
About 100.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.19. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Vaxcyte recorded a loss per share of 3.8. The entity had not issued any dividends in recent years. Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. Vaxcyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people. To find out more about Vaxcyte contact Grant MBA at 650 837 0111 or learn more at https://vaxcyte.com.Besides selling stocks to institutional investors, Vaxcyte also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Vaxcyte's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Vaxcyte's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Vaxcyte Quarterly Liabilities And Stockholders Equity |
|
Vaxcyte Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vaxcyte is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vaxcyte backward and forwards among themselves. Vaxcyte's institutional investor refers to the entity that pools money to purchase Vaxcyte's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | T. Rowe Price Investment Management,inc. | 2024-12-31 | 2.9 M | Geode Capital Management, Llc | 2024-12-31 | 2.8 M | Westfield Capital Management Company, L.p. | 2024-12-31 | 2.6 M | Kynam Capital Management, Lp | 2024-12-31 | 2.3 M | Alliancebernstein L.p. | 2024-12-31 | 1.8 M | Jpmorgan Chase & Co | 2024-12-31 | 1.7 M | Perceptive Advisors Llc | 2024-12-31 | 1.7 M | Commodore Capital Lp | 2024-12-31 | 1.6 M | Paradigm Biocapital Advisors Lp | 2024-12-31 | 1.4 M | Fmr Inc | 2024-12-31 | 13.1 M | Vanguard Group Inc | 2024-12-31 | 12 M |
Vaxcyte Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vaxcyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vaxcyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vaxcyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vaxcyte Outstanding Bonds
Vaxcyte issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vaxcyte uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vaxcyte bonds can be classified according to their maturity, which is the date when Vaxcyte has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Vaxcyte Corporate Filings
| 17th of April 2025 Other Reports | ViewVerify | |
F4 | 10th of April 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 31st of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.